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Background: Physical activity (PA) is recommended as part of the treatment regimen for cystic ﬁbrosis (CF) although objective methods have been
scarcely used to monitor achievement of PA guidelines.
Methods: PA was measured by accelerometer in outpatient CF children (n = 47) and results were compared with those obtained in age- and
gender-matched healthy controls (n = 39).
Results: 2.1% of the outpatients fulﬁlled PA guidelines (i.e. ≥60 min·day−1 of moderate-to-vigorous PA (MVPA)) vs. 34.2% of controls. Overall,
lower MVPA levels were observed in CF patients than controls despite the former undergoing more light or total PA. Peak oxygen uptake was also
lower in the CF group than in controls (37.5 ± 7.8 vs. 43.5 ± 7.6 ml·kg−1·min−1, p = 0.002) and was correlated with MVPA and vigorous PA in
the former.
Conclusions: These ﬁndings support a need to promote PA interventions (including MVPA) targeted at improving cardiorespiratory ﬁtness in CF
children.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Physical activity; Guidelines; Cardiorespiratory ﬁtness1. Introduction
Cystic fibrosis (CF) is an inherited genetic disorder that
leads to progressive deterioration of lung function and physical
capacity; it affects approximately one in 2500 newborns [1].
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;lished31 years [2]. Regular physical activity (PA) has become
increasingly important and widely accepted as part of the
therapy and rehabilitation programs in CF management [3];
although, PA remains underutilized and not always incorpo-
rated into routine CF management [3]. Several studies have
reported beneficial effects of exercise training that include:
slower lung function decline [4], enhanced airway clearance
[5], improved nutritional status and quality of life [6] and
reduced hospital admissions [7]. The additional training
benefits for CF patients do not differ from those for healthy
individuals and include mainly improved aerobic fitness and
muscle strength [8,9].by Elsevier B.V. All rights reserved.
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aerobic fitness (as determined by peak oxygen uptake, VO2peak)
[10] and higher aerobic fitness is a predictor of survival in this
disease [11–15]. It is consequently of medical interest to
quantify actual PA levels in children with CF to help prescribe
PA programs designed to improve their aerobic fitness.
Current guidelines indicate that children and adolescents
should engage in at least 60 min of moderate to vigorous PA
(MVPA) daily [16]. However, given that many children fail to
reach this level of activity [17], there is a need to ensure that
youths are meeting the PA guidelines recommended for optimal
health outcomes. This is especially important in CF children;
however, despite the known impact of PA on the health and
quality of life of these children, there has been relatively little
research evaluating the PA levels of this patient group. One
of the reasons for this deficiency is that assessing PA in
children using self- or parent-administered questionnaires has
many limitations; children find it especially difficult to describe
or quantify their PA levels [18]. Such limitations have led to an
increasing interest in the use of more objective methods to
monitor PA. As opposed to questionnaires, accelerometers can
provide minute-by-minute recordings of PA and can therefore
be used to objectively quantify PA [19].
To date, there are studies in which PA levels in children
[6,20] or adults [21] with CF have been measured objectively
by accelerometers. Yet the studies in CF children have some
methodological limitations, i.e. use of activity counts rather
than activity cut-point thresholds to quantify activity intensity
[6] or insufficient number of accelerometer wearing days for
appropriate PA analysis [20]. This situation makes it difficult
to determine if children were performing light, MVPA or
vigorous PA. There is a need for longer periods of monitoring
PA objectively and the use of intensity cut-points to obtain
information on usual PA levels in children with CF (including the
comparison of weekend vs. weekday activity behavior) and on
how well these patients comply with current PA guidelines. Such
data would add valuable information to the existing literature and
help health carers recommend PA more effectively.
The purpose of our study was to objectively measure PA
levels in outpatient children with CF vs. age and gender-matched
healthy controls over a week (as well as on week days vs.
weekends), and to determine the proportion of them meeting the
PA guidelines (primary outcome). VO2peak was also determined
in the two groups to examine its possible correlation with PA
(secondary outcome). We hypothesized that children undergoing
treatment for CF would show overall reduced MVPA levels
compared to their healthy peers, with the majority of the former
not meeting the PA guidelines.2. Materials and methods
2.1. Participants
The research project was in accordance with the Declaration
of Helsinki Research of 1974 (last modified in 2008) and
was approved by the corresponding Review Board (Children'sHospital Niño Jesús; Madrid, Spain). Informed consent was
obtained from the parents of each participant.
Participants were recruited by screening the medical records
of this hospital's Pneumology department to select 113 children
under treatment for CF. After the corresponding pneumologist
provided consent, subjects were enrolled in the study if they
met each of the inclusion criteria: outpatient diagnosed using a
genetic test for CF and treated at the aforementioned hospital,
and boy/girl aged 6–17 years living in the Madrid region
(so that they could attend VO2peak testing sessions). Exclusion
criteria were: having severe lung deterioration (forced expira-
tory volume (FEV1) b 50% the expected value), an unstable
clinical condition (i.e. hospitalization within the previous
3 months), Burkholderia cepacia infection, or any condition
(e.g. muscle–skeletal disorder) impairing exercise testing.
According to these criteria, 73 children with CF were originally
enrolled in the study; valid accelerometry data was obtained in
47 (see Fig. 1 for the flow diagram of the participants in the CF
group) of whom 39 had also undergone a cardiorespiratory
fitness test (see below).
The data of the CF children were compared to those of 39
age and gender-matched controls with complete accelerometry
and VO2peak data (see below) pooled from a total cohort of
118 children living in the same neighborhood. The same
measurements (using the same methodology and equipment)
were performed in the two groups during years 2010–2012,
as explained below. Anthropometric and cardiorespiratory
fitness evaluations were performed in the exercise physiology
laboratory of the Children's Hospital Niño Jesús (CF group)
and of the European University of Madrid (control group).
2.2. Measurements
2.2.1. Anthropometric data
Height without shoes was measured using a clinical
stadiometer (Asimed T2, Barcelona, Spain) and recorded to the
nearest millimeter. Body mass was determined to the nearest
0.05 kg using a balance scale (Ano Sayol S.L., Barcelona, Spain)
with subjects in their underwear. Body mass index (BMI) was
calculated as weight/height (kg·m−2). Skinfold thickness was
measured with a Harpenden caliper (Holtan Crymych, United
Kingdom) at the biceps, triceps, sub-scapular, abdominal,
supra-iliac, thigh and calf areas following the criteria described
elsewhere [22]. Percentage of body fat [23] was calculated from
body density values using age- and gender-specific equations,
i.e. for boys and girls aged ≤11 years [24], 12–15 years [25],
and 16–18 years [26].
2.2.2. Accelerometry
PA was planned to be measured on 7 consecutive days
(Thursday to Wednesday or Friday to Thursday) using the
Actigraph GT3X accelerometer (Actigraph, Pensacola, FL,
USA). All children wore the accelerometer in an elastic
waistband on their right hip during the day, except while
bathing or undertaking other water activities. Verbal and
written instructions for the care and placement of the monitor
were given to both the children and their parents. The GT3X is
N = 73 
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Age <6 years or > 18 
years (N= 26) 
Burkholdelia cepacia
infection in the past 3  
years (N=14)
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3 children lost  their 
accelerometers
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Accelerometry data
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data
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Outpatient children under treatment for  
cystic fibrosis at the Niño Jesús  
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Fig. 1. Flow diagram of the patient recruitment process.
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accelerometer. Movement in the three axes is detected as a
combined function of the frequency and intensity of the
movement, while an electronic filter rejects motion outside
the range of normal human movement. This accelerometer has
proven valid and reliable for the determination of PA in
children [27].
For each participant, a minimum of 4 days' monitoring
including one weekend day, and a minimum of 10 h of
complete accelerometry data per day, were considered necessary
for PA assessment to be considered valid and thus for their
accelerometry data to be included in the study [28]. Epoch
duration or the sampling period was set at 15 s, and we applied
cut-points (see below) to the 15-second epochs (after dividing by
four); output was expressed as counts per minute (counts·min−1).
Following recent recommendations for accelerometry research
conducted in children and adolescents [29], count ranges for
the various activity intensities were determined using the
cut-points originally developed by Evenson et al. [30]: 0 to 100
counts·min−1 for sedentary activity, 101 to 2295 counts·min−1
for light PA, 2296 to 4011 counts·min−1 for moderate PA
and N4012 counts·min−1 for vigorous PA. To analyze theaccelerometer data, Kinesoft software, developed specifically
for the Actical and Actigraph accelerometers, was used. The
outcome variables were expressed in time (min·day−1) spent for
the different PA-intensity categories. Thus, we calculated how
many minutes of light, and moderate and vigorous activity were
performed by the children during the full week, as well as on
week and weekend days. We excluded from the analysis bouts of
20 continuous minutes of activity with intensity counts of 0,
considering these periods to be non-wearing time [28].
2.2.3. VO2peak
Children performed a graded exercise test on a treadmill
(Technogym Run Race 1400HC; Gambettola, Italy) to determine
VO2peak. Before the test, they undertook at least one practice
session. All the exercise tests were conducted under similar
environmental conditions (temperature of 20 to 24 °C, relative
humidity of 45 to 55%). Gas-exchange data were measured
breath-by-breath by open circuit spirometry using pediatric
face-masks (Vmax 29C, Sensormedics; Yorba Linda, CA, USA).
Peak oxygen uptake (VO2peak) was recorded as the highest mean
VO2 value obtained for any continuous 20-second period. Heart
rate (HR) was continuously monitored during the tests from a
Table 1
Anthropometric and cardiorespiratory data by group.
CF group Control group
No. with complete data Result No. with complete data Result p-Value
Anthropometric variables
Weight (kg) 47 40.1(11.7) 39 45.1(12.3) 0.07
Height (cm) 47 146.9(15.8) 39 150.4(14.8) 0.30
BMI (kg·m−2) 47 18.6(2.8) 39 19.9(2.1) 0.07
∑ skinfolds (mm) 47 77.5(31.5) 39 85.5(32.4) 0.31
Fat mass (%) 47 19.8(5.9) 39 21.8(6.0) 0.17
Fat free mass (%) 47 80.2(5.8) 39 78.2(6.0) 0.17
Cardiorespiratory fitness
VO2peak (ml·kg
−1·min−1) 39 37.5(7.8) 39 43.5(7.6) 0.002
Data expressed as mean(SD). Abbreviations: BMI, body mass index; CF, cystic fibrosis; VO2peak, peak oxygen uptake. Significant between-group differences appear
in bold.
Table 2
Physical activity (PA) data by group.
CF group
(n = 47)
Control group
(n = 39)
p-Value
Average monitoring time (min·day−1) 725(74) 764(97) 0.249
All week
Sedentary time (min·day−1) 362(67) 484(85) b0.001
Total PA (min·day−1) 363(85) 280(58) 0.001
Light PA (min·day−1) 319(71) 226(44) 0.040
MVPA (min·day−1) 44(28) 54(15) 0.020
Vigorous PA (min·day−1) 9(6) 17(9) 0.001
Week days
Sedentary time (min·day−1) 407(73) 300(101) b0.001
Total PA (min·day−1) 361(90) 283(35) b0.001
Light PA (min·day−1) 315(63) 226(44) 0.001
MVPA (min·day−1) 46(33) 57(19) 0.60
Vigorous PA (min·day−1) 8(9) 17(9) b0.001
Weekend days
Sedentary time (min·day−1) 355(79) 463(83) b0.001
Total PA (min·day−1) 355(96) 275(79) b0.001
Light PA (min·day−1) 319(77) 230(62) b0.001
MVPA (min·day−1) 36(32) 45(20) 0.164
Vigorous PA (min·day−1) 8(9) 16(6) 0.01
Data expressed as mean(SD). Abbreviations: CF, cystic fibrosis; MVPA,
moderate-to-vigorous physical activity; PA, physical activity. Significant
between-group differences appear in bold.
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smaller children, height b120 cm) or 2.5 km·h−1 (if children's
height was N120 cm) at a 0.5% gradient. Thereafter, both
treadmill speed and gradient were increased (by 0.1 km·h−1 and
0.5% respectively) every 15 s. The tests were terminated upon
volitional fatigue, when the child was unable to keep up the
required workload, or if the child suffered a coughing fit [23]. All
the children were verbally encouraged and had no visual access to
their parents.
2.3. Statistical analysis
Data are provided as mean ± standard deviation (SD).
Tests of normality, symmetry and kurtosis were performed.
Between-group differences in PA data were assessed using
independent Student's t-tests. Chi-square tests were used to
examine differences between the two groups in terms of
fulfilling PA guidelines. Correlations between PA variables and
VO2peak were examined by ordinary least squares (OLS) linear
regression. All statistical tests were performed using the PASW
software (v. 19.0 for WINDOWS, Chicago). Significance was
set at p b 0.05.
3. Results
The main descriptive data for the study groups are provided
in Table 1. A full set of accelerometry data was obtained in 47
CF children (24 boys, 23 girls, mean age: 12 ± 3 years). Of
these, VO2peak was recorded in 39 (23 boys). The control group
(n = 39) included 23 boys and 16 girls aged 12 ± 2 years. The
children's anthropometric data did not differ between the two
groups (all p N 0.1). Mean VO2peak was significantly higher in
the control group than in the CF group (p = 0.002).
PA data are shown in Table 2. No significant difference was
found between the two groups in minutes of total accelerometry
time registered per day. Sedentary time was significantly higher
for the control group when all week, week days and weekend
days were considered (all p = b0.001). Total PA and light PA
levels for the whole week were significantly higher (p = 0.001
and p = 0.040 respectively) in patients than controls. However,
weekly vigorous PA and MVPA were significantly lower in theformer (p = 0.001 and p = 0.020 respectively). Significant
differences were also detected when separated analysis were
done for week days and weekend days. Thus, during week
days, the CF group undertook more total (p b 0.001) and light
PA than the control group (p = 0.001), but spent less sedentary
time (p b 0.001), as well as vigorous PA (p b 0.001). Similar
differences between the two groups were found during weekend
days.
Overall, 34.2% (n = 13) vs. 2.1% (n = 1) of children in the
control and CF group respectively met the MVPA guidelines
(p b 0.001) (Fig. 2). The percentages of children fulfilling
MVPA guidelines during week (p b 0.001) or weekend days
(p = 0.04) were also lower in the CF group.
In the CF group, VO2peak was significantly correlated with
all-week MVPA (r = 0.46, p = 0.003) and all-week vigorous
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Fig. 2. Percentages of children meeting recommendations for moderate-to-
vigorous physical activity (MVPA) by group. *p b 0.001, **p = 0.04 for
between-group comparisons. Abbreviation: CF, cystic fibrosis.
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weekend days, VO2peak was also significantly correlated with
MVPA (r = 0.41, p = 0.009 and r = 0.39, p b 0.05 respectively)
and vigorous PA (r = 0.38, p b 0.05 and r = 0.35, p b 0.05
respectively). No significant correlations between PA and
VO2peak were found in the control group except for vigorous
PA on weekend days (r = 0.35; p b 0.05).
4. Discussion
The main finding of our study was that, overall, the children
with CF spent less time undertaking intense PA compared to
the age-matched controls; moreover, children with CF had a
lower achievement of PA guidelines. Compared to controls, CF
group spent significantly more time in light PA and total PA but
less time in MVPA and vigorous PA. Current PA guidelines
recommend that children engage in at least 60 min and up to
several hours of MVPA on all or most days of the week [16].
Only one child with CF fulfilled this PA guideline during the
whole week and a very small proportion of the patients (4.3%)
met the guideline on week days. A larger proportion (23.9%)
met the guideline during weekends. Among the control children
~59% fulfilled the PA guideline on week days and ~34% met
the guideline during all week. When considering the total
amount of light PA and total activity performed, the key
difference emerging between the groups was the intensity
rather than the quantity of PA performed over a full week. In
other words, the children with CF engaged in a reasonable
quantity of PA (i.e. total PA) but this PA was of insufficient
quality (i.e. MVPA and vigorous PA) to meet general PA
recommendations.
The PA results of this study did not agree, at least
apparently, with those of Kilbrige et al. (2012) [20] and
Selvadurai et al. (2004) [6], where patients with CF were as
active and fit as their healthy controls. With regard to this, there
is evidence [31] that a minimum of 7-day monitoring is needed
to provide a reliable estimate of usual PA behavior in children
and adolescents and to assess differences in weekend vs. week
day activity behavior, yet the study by Kilbrige et al. [20] only
used 3 days of monitoring PA. Moreover, the use of counts and
a global measure of PA instead of the amount of minutes of
light, moderate or vigorous PA could have altered the results ofprevious research [6], together with the use of different types of
accelerometer among studies. RT3 accelerometers used in
Kilbride et al. [20] were compared to the Actigraph acceler-
ometers and SenseWear Armband (SWA) in free-living energy
expenditure (EE) within sedentary environments [32] and the
RT3 model was found to be less valid for quantifying EE
during light-intensity activities than Actigraph accelerometers
and SWA. Recently, Rabinovich and colleagues [33] have
recommended the use of GT3X Actigraph accelerometer as the
most valid monitor to measure daily life PA in patients with
chronic obstructive pulmonary disease.
Our results are in agreement with those of Nixon et al.
(2001) [34] where children with CF engaged in less vigorous
PA than their healthy non-CF peers, despite having good lung
function. However, comparisons between studies are difficult
because they used a questionnaire (i.e. Kriska's Modifiable
Activity Questionnaire) to estimate PA. Similar results have
been found in young adults [21] where subjects wore a SWA
during 5–7 days, and they reported that the amount of PA
above moderate intensity was significantly reduced in CF
compared with controls, which could imply that the differences
found in our study may be still present in young adulthood.
Fulfillment of the above-mentioned PA guideline in Spanish
children [17] has been separately analyzed for 9- and 15-year-
old children: the guideline was met in 60% of the boys and
34.1% of the girls (9-year-olds) and in 28.8% of the boys and
8.9% of the girls (15-year-olds). This same study reported a
higher rate of guideline fulfillment during week days versus
weekend days. The control children examined here showed a
similar pattern. In contrast, our CF patients were better able to
fulfill the PA guideline during weekends. Parents' awareness of
the need that their CF children engage in vigorous PA might
explain, at least partly, higher fulfillment of guidelines during
weekends, when parents have more time to share with their
children and can have a more proactive role in outdoor activities
and sports playing.
VO2peak was significantly correlated with all-week, week-day
andweekend dayMVPA and vigorous PA in our CF group. Good
aerobic fitness (as determined by VO2peak) is a predictor of
survival in CF [12] such that this correlation highlights a need to
promote higher intensities of PA. Research has demonstrated the
benefits of aerobic and strength exercise training programs for
health and quality of life. However, the CF patient has to face
challenges and even barriers to participate in PA programs. Mean
VO2peak levels are usually lower in patients with CF compared
with their healthy counterparts [34]. This variable is an important
predictor of mortality in these patients [12,14]. Thus, mortality is
high in children with VO2peak values of b32 ml·kg
−1·min−1 (60%
after 8 years) whereas it is null in those with VO2peak levels of
N45 ml·kg−1·min−1 [12,14]. In our study, 23.1% (n = 9) of the
children with CF had a VO2peak lower than 32 ml·kg
−1·min−1;
59% (n = 23) of patients had a VO2peak between 32 and
45 ml·kg−1·min−1, and only in 17.9% (n = 7) was this indicator
higher than 45 ml·kg−1·min−1. These data support the notion that
PA interventions (including vigorous PA) aimed at improving
cardiorespiratory fitness in child CF patients are urgently needed,
at least in Spanish CF patients.
340 S. Aznar et al. / Journal of Cystic Fibrosis 13 (2014) 335–340In conclusion, we observed that only 2.1% of children
undergoing treatment for CF achieved PA guidelines. Overall,
compared to controls they performed a greater quantity of PA
(i.e. minutes of total PA) but this PA was of insufficient
intensity. These findings prompt a need to encourage children
with this illness to participate in sports, games and activities
that involve bouts of vigorous PA from an early age.
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